CD274 and endometrial cancer: Clinical studies of single or combined treatment for endometrial cancer with PARP inhibitors, as well as PD-1 and PD-L1 inhibitors have been reported, which may bring new perspectives to the treatment of metastatic or recurrent endometrial cancer (Karpel et al., 2023; Rowlands et al., 2023).